Inotiv, Inc. Share Price

Equities

NOTV

US45783Q1004

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
4.05 USD -5.59% Intraday chart for Inotiv, Inc. -6.25% +10.35%
Sales 2024 * 581M 46.5B Sales 2025 * 602M 48.18B Capitalization 104M 8.36B
Net income 2024 * -29M -2.32B Net income 2025 * -27M -2.16B EV / Sales 2024 * 0.18 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.17 x
P/E ratio 2024 *
-3.52 x
P/E ratio 2025 *
-3.82 x
Employees 2,005
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.59%
1 week-6.25%
Current month-62.98%
1 month-59.66%
3 months+23.10%
6 months+104.55%
Current year+10.35%
More quotes
1 week
3.97
Extreme 3.97
5.25
1 month
3.97
Extreme 3.97
11.20
Current year
3.18
Extreme 3.18
11.42
1 year
1.61
Extreme 1.61
11.42
3 years
1.61
Extreme 1.61
60.66
5 years
1.61
Extreme 1.61
60.66
10 years
0.60
Extreme 0.6
60.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 11/01/19
Director of Finance/CFO 59 05/03/20
Chief Operating Officer 58 14/02/21
Members of the board TitleAgeSince
Director/Board Member 68 31/07/17
Director/Board Member 68 23/01/23
Chairman 70 13/06/17
More insiders
Date Price Change Volume
26/04/24 4.05 -5.59% 328,347
25/04/24 4.29 -8.14% 523,273
24/04/24 4.67 -3.71% 418,578
23/04/24 4.85 +9.73% 649,523
22/04/24 4.42 +2.31% 563,694

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.05 USD
Average target price
15.5 USD
Spread / Average Target
+282.72%
Consensus